Oroxylum indicum Composition for Chemotherapy-Induced Hypertriglyceridemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective natural molecules or combinations to decrease triglyceride levels specifically in hypertriglyceridemia induced by chemotherapeutics and hyperglycemia.
Innovation Solution
A composition comprising at least 10% w/w of oroxylin A, 10% w/w of baicalein, and 2% w/w of chrysin is administered to manage hypertriglyceridemia, particularly in cases caused by chemotherapeutics and hyperglycemia, formulated with pharmaceutically acceptable excipients for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for hypertriglyceridemia, then general triglyceride reduction may be achieved, but effective treatment of hypertriglyceridemia induced by chemotherapeutics and hyperglycemia is lacking
Solution Approach 1:
The patent applies local quality by developing a treatment specifically tailored for hypertriglyceridemia induced by chemotherapeutics and hyperglycemia, rather than using general treatments. The composition of oroxylin A, baicalein, and chrysin is optimized to address the specific pathological mechanisms of this subtype, making the treatment effective for this particular condition while acknowledging that other causes of hypertriglyceridemia may require different approaches.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical composition parameters - specifically using a defined ratio of oroxylin A (10-30%), baicalein (10-30%), and chrysin (2-10%). These specific concentration ranges were determined to be optimal for treating chemotherapy and hyperglycemia-inducedhypertriglyceridemia, demonstrating how changing compositional parameters can achieve targeted therapeutic effects for specific disease subtypes.
2Reliability
If a combination of multiple natural molecules is used, then therapeutic effectiveness may be improved, but formulation complexity increases
Solution Approach 1:
The patent applies merging by combining three natural molecules - oroxylin A, baicalein, and chrysin - into a single integrated composition. These compounds work synergistically to address multiple aspects of hypertriglyceridemia pathophysiology, including lipid metabolism regulation and anti-inflammatory effects. The merging of these complementary agents creates a more effective treatment than any single compound alone, while the fixed ratio formulation simplifies the dosing and administration complexity.
Data Source
AI summary
The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of hypertriglyceridemia, associated with chemotherapy and hyperglycemia.